Promising Prospects for Revolution Medicines: Buy Rating Affirmed on Daraxonrasib’s CNPV Designation
I'm PortAI, I can summarize articles.
Charles Zhu has affirmed a Buy rating for Revolution Medicines, citing the promising prospects of daraxonrasib, which has received the FDA's CNPV designation. This designation indicates significant potential to address national health priorities and may expedite the drug's approval process. With Phase 3 RASolute topline data expected in 2026, there is a strong possibility for approval and launch by year-end. Barclays also maintains a Buy rating with a $72.00 price target, reflecting positive sentiment in the healthcare sector.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments